CN104583225A - 艾杜糖-2-硫酸酯酶的纯化 - Google Patents

艾杜糖-2-硫酸酯酶的纯化 Download PDF

Info

Publication number
CN104583225A
CN104583225A CN201380042665.2A CN201380042665A CN104583225A CN 104583225 A CN104583225 A CN 104583225A CN 201380042665 A CN201380042665 A CN 201380042665A CN 104583225 A CN104583225 A CN 104583225A
Authority
CN
China
Prior art keywords
restructuring
purifying
methods according
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380042665.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·尼科尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Human Genetics Therapies Inc
Original Assignee
Shire Human Genetics Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104583225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetics Therapies Inc filed Critical Shire Human Genetics Therapies Inc
Priority to CN201710840314.6A priority Critical patent/CN107596357A/zh
Priority to CN201710840704.3A priority patent/CN107596358A/zh
Publication of CN104583225A publication Critical patent/CN104583225A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201380042665.2A 2012-06-29 2013-06-28 艾杜糖-2-硫酸酯酶的纯化 Pending CN104583225A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710840314.6A CN107596357A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化
CN201710840704.3A CN107596358A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
US61/666,733 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710840314.6A Division CN107596357A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化
CN201710840704.3A Division CN107596358A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化

Publications (1)

Publication Number Publication Date
CN104583225A true CN104583225A (zh) 2015-04-29

Family

ID=49778401

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380042665.2A Pending CN104583225A (zh) 2012-06-29 2013-06-28 艾杜糖-2-硫酸酯酶的纯化
CN201710840314.6A Pending CN107596357A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化
CN201710840704.3A Pending CN107596358A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710840314.6A Pending CN107596357A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化
CN201710840704.3A Pending CN107596358A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化

Country Status (39)

Country Link
US (7) US9051556B2 (enExample)
EP (2) EP3441398A1 (enExample)
JP (4) JP6171007B2 (enExample)
KR (5) KR101380740B1 (enExample)
CN (3) CN104583225A (enExample)
AR (1) AR091647A1 (enExample)
AU (3) AU2013282395C1 (enExample)
BR (1) BR112014032567B1 (enExample)
CA (2) CA3008945A1 (enExample)
CL (1) CL2014003567A1 (enExample)
CO (1) CO7240396A2 (enExample)
CR (1) CR20140588A (enExample)
CY (1) CY1121519T1 (enExample)
DK (1) DK2867245T3 (enExample)
DO (1) DOP2014000294A (enExample)
EA (2) EA202090044A1 (enExample)
ES (1) ES2689468T3 (enExample)
GT (1) GT201400303A (enExample)
HK (3) HK1209431A1 (enExample)
HR (1) HRP20181897T1 (enExample)
HU (1) HUE040769T2 (enExample)
IL (4) IL236315A (enExample)
LT (1) LT2867245T (enExample)
MX (3) MX393364B (enExample)
MY (3) MY157087A (enExample)
NZ (3) NZ733366A (enExample)
PE (1) PE20150720A1 (enExample)
PH (3) PH12014502871A1 (enExample)
PL (1) PL2867245T3 (enExample)
PT (1) PT2867245T (enExample)
RS (1) RS58005B1 (enExample)
SG (2) SG11201408761VA (enExample)
SI (1) SI2867245T1 (enExample)
SM (1) SMT201800612T1 (enExample)
TR (1) TR201815811T4 (enExample)
TW (2) TWI587869B (enExample)
UA (2) UA121959C2 (enExample)
WO (1) WO2014005014A2 (enExample)
ZA (2) ZA201409397B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045727A1 (zh) * 2016-09-06 2018-03-15 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
AU2017316955B2 (en) 2016-08-25 2022-03-03 Jcr Pharmaceuticals Co., Ltd. Method for producing antibody fusion protein
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
JP7458404B2 (ja) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド イズロン酸－２－スルファターゼ免疫グロブリン融合タンパク質の精製
AU2020216368B2 (en) * 2019-01-30 2025-04-24 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
JP2023504208A (ja) 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
MX2023004621A (es) * 2020-10-23 2023-06-06 Alexion Pharma Inc Método de control del contenido total de ácido siálico (ctas) durante la fabricación de fosfatasa alcalina.
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096555A (en) * 1995-07-26 2000-08-01 Dade Behring Marburg Gmbh Process for characterizing the glycosylation of glyco-proteins and for the in vitro determination of the bio-availability of glyco-proteins
US7323553B2 (en) * 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
US7541164B2 (en) * 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011044542A1 (en) * 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011163652A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
PT1171615E (pt) 1999-04-26 2007-03-30 Genentech Inc Processo de cultura celular para glicoproteínas
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
EP1212343A4 (en) 1999-09-03 2004-11-03 Human Genome Sciences Inc 52 HUMAN SECRETED PROTEINS
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
JP2004502404A (ja) 2000-02-17 2004-01-29 インサイト・ゲノミックス・インコーポレイテッド ヒトキナーゼ
WO2001070804A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
EP1592786B8 (en) 2003-02-11 2012-03-21 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies using a formylglycine generating enzyme (fge)
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
EP2532742B1 (en) 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
KR20080111487A (ko) 2006-03-20 2008-12-23 메다렉스, 인코포레이티드 단백질 정제 방법
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
PL3626258T3 (pl) 2010-06-25 2022-01-17 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012042857A1 (ja) 2010-09-28 2012-04-05 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096555A (en) * 1995-07-26 2000-08-01 Dade Behring Marburg Gmbh Process for characterizing the glycosylation of glyco-proteins and for the in vitro determination of the bio-availability of glyco-proteins
US7323553B2 (en) * 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
US7541164B2 (en) * 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2011044542A1 (en) * 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011163652A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045727A1 (zh) * 2016-09-06 2018-03-15 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用

Also Published As

Publication number Publication date
DOP2014000294A (es) 2015-03-15
ES2689468T3 (es) 2018-11-14
JP2016119911A (ja) 2016-07-07
MY180287A (en) 2020-11-27
IL236315A (en) 2016-11-30
SI2867245T1 (sl) 2018-12-31
KR101380740B1 (ko) 2014-04-11
MX2019008914A (es) 2019-09-26
MX336715B (es) 2016-01-28
EA202090044A1 (ru) 2020-07-31
ZA201803289B (en) 2021-04-28
HUE040769T2 (hu) 2019-03-28
BR112014032567A2 (pt) 2017-08-01
NZ743910A (en) 2019-12-20
DK2867245T3 (en) 2018-11-26
JP2015523072A (ja) 2015-08-13
SG11201408761VA (en) 2015-01-29
PE20150720A1 (es) 2015-05-16
US11530393B2 (en) 2022-12-20
TWI587869B (zh) 2017-06-21
MY157087A (en) 2016-04-19
PH12015502408A1 (en) 2018-03-26
TW201703794A (zh) 2017-02-01
MX366906B (es) 2019-07-30
PH12015502408B1 (en) 2020-02-14
CL2014003567A1 (es) 2015-04-24
US20240043817A1 (en) 2024-02-08
CY1121519T1 (el) 2020-05-29
PH12014502871B1 (en) 2015-02-23
KR20140002451A (ko) 2014-01-08
IL261264A (en) 2018-10-31
JP2020105209A (ja) 2020-07-09
HK1209431A1 (en) 2016-04-01
PH12020500027A1 (en) 2021-03-15
KR20220002227A (ko) 2022-01-06
MY192068A (en) 2022-07-25
AU2018200230B2 (en) 2020-01-02
TWI553120B (zh) 2016-10-11
AU2018200230A1 (en) 2018-02-01
PH12014502871A1 (en) 2015-02-23
TW201410868A (zh) 2014-03-16
US20150313972A1 (en) 2015-11-05
RS58005B1 (sr) 2019-02-28
CA2877517A1 (en) 2014-01-03
HK1209767A1 (en) 2016-04-08
IL248727A0 (en) 2017-01-31
WO2014005014A3 (en) 2014-02-27
NZ703093A (en) 2017-08-25
AU2016200469A1 (en) 2016-02-18
US20170073652A1 (en) 2017-03-16
KR20140004603A (ko) 2014-01-13
EP2867245A2 (en) 2015-05-06
NZ733366A (en) 2019-12-20
UA129561C2 (uk) 2025-06-04
BR112014032567B1 (pt) 2022-09-13
CA2877517C (en) 2018-07-31
US20140004096A1 (en) 2014-01-02
US10344270B2 (en) 2019-07-09
TR201815811T4 (tr) 2018-11-21
LT2867245T (lt) 2018-11-12
HRP20181897T1 (hr) 2019-01-11
HK1249026A1 (zh) 2018-10-26
JP2018121645A (ja) 2018-08-09
ZA201409397B (en) 2019-10-30
AU2013282395B2 (en) 2015-12-03
PT2867245T (pt) 2018-11-26
US20210317426A1 (en) 2021-10-14
KR20190064542A (ko) 2019-06-10
CA3008945A1 (en) 2014-01-03
KR20200143339A (ko) 2020-12-23
AU2016200469B2 (en) 2017-10-12
CO7240396A2 (es) 2015-04-17
PL2867245T3 (pl) 2019-02-28
UA121959C2 (uk) 2020-08-25
US12359178B2 (en) 2025-07-15
MX2015000190A (es) 2015-04-08
AR091647A1 (es) 2015-02-18
IL236315A0 (en) 2015-02-26
WO2014005014A2 (en) 2014-01-03
EA201492177A1 (ru) 2015-06-30
IL287057A (en) 2021-12-01
SMT201800612T1 (it) 2019-01-11
US20190359958A1 (en) 2019-11-28
HK1249027A1 (zh) 2018-10-26
EP3441398A1 (en) 2019-02-13
AU2013282395A1 (en) 2015-01-29
EP2867245A4 (en) 2016-03-09
GT201400303A (es) 2017-08-31
AU2013282395C1 (en) 2016-03-24
EA034549B1 (ru) 2020-02-19
EP2867245B1 (en) 2018-09-12
CN107596357A (zh) 2018-01-19
US9051556B2 (en) 2015-06-09
JP7594365B2 (ja) 2024-12-04
MX393364B (es) 2025-03-19
SG10201703489VA (en) 2017-05-30
CR20140588A (es) 2015-04-06
JP6505629B2 (ja) 2019-04-24
US9492511B2 (en) 2016-11-15
IL261264B (en) 2021-10-31
JP6171007B2 (ja) 2017-07-26
CN107596358A (zh) 2018-01-19
US20240401010A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
US12359178B2 (en) Methods and compositions for treatment of hunter syndrome comprising iduronate-2-sulfatase
HK1209767B (en) Purification of iduronate-2-sulfatase
EA049401B1 (ru) Очистка идуронат-2-сульфатазы

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1209431

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150429

RJ01 Rejection of invention patent application after publication